SAN ANTONIO, June 3, 2011 /PRNewswire/ — At the 2011 SNM
Annual Meeting in San Antonio, Siemens Healthcare (booth #6033)
will address the increasing demand for molecular imaging procedures
and Siemens’ efforts to expand molecular imaging’s availability in
three directions: patient access, clinical utilization, and new
clinical applications. Through this benchmark-redefining growth of
molecular imaging, Siemens (NYSE:
SI) is “Expanding Your Return on Innovation.”
(Logo:
http://photos.prnewswire.com/prnh/20070904/SIEMENSLOGO)
Expanded Clinical Utilization
Two of the most challenging issues facing physicians who are
expanding their clinical utilization of molecular imaging scanners
are the dual mandates to improve patient safety and increase
productivity. Siemens is meeting both of these core needs through
its commitment to minimizing dose while maximizing speed. Siemens
offers innovative solutions where the lowest dose can be used,
while still scanning patients faster than ever.
Symbia® IQ-SPECT technology, which recently received the
2011 North American Nuclear Cardiology Product Differentiation
Excellence of the Year Award from the business research and
consulting firm of Frost & Sullivan, enables routine scans
using half dose and double speed. Its proven technologies provide a
comprehensive cardio workup, while easing the burden of the global
molybdenum shortage via a reduction in technetium dose. Diagnostic
SPECT-CT, including calcium scoring, uses half of the typical
technetium dose and cuts acquisition time from approximately 20
minutes to less than five minutes with the addition of
IQ–SPECT.
With technologies such as TrueV and ultraHD-PET, where the axial
field of view is increased by 33%, and 2mm uniform resolution
across the entire field of view is achieved, along with two times
improvement in signal to
‘/>”/>
SOURCE